Home > Resources > Whitepapers > Metabolic Disease Research (CCMDR) and the Weizmann Institute of Science

Metabolic Disease Research (CCMDR) and the Weizmann Institute of Science

A research workshop dedicated to metabolic disease research, with a specific emphasis on diabetes (T1D and T2D) and obesity, was held at The University of Connecticut, Department for Cell and Genome Sciences in Farmington, Connecticut, on April 11-12, 2016. The event was co-sponsored by The Jackson Laboratory (JAX), Yale University and the University of Connecticut (UConn) and included scientists from the Weizmann Institute of Science.

Spotlight

Alchemia Limited

Alchemia Limited is a listed Australian biotechnology company (ASX:ACL). The Company has particular expertise in chemistry, which it has applied to the discovery and development of human therapeutic products

OTHER WHITEPAPERS

Vaccine and Biologics Development in an Emerging Post Pandemic Landscape

whitePaper | September 20, 2022

It is clear within the global health science industry that analytical biosafety testing and advances in developing scientific technologies will play an important role in drug development’s response to the next pandemic.

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.